CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the stock up about 2% over the past day but showing declines over the past week ...

CRISPR Therapeutics AG reported a Q1 net loss of $136m, but maintains a strong cash position with $1.86bn in cash and marketable securities. Casgevy, a gene therapy for Sickle Cell Disease, has seen ...

Future AI-guided genomic analysis offers the potential to further optimize gene constructs, expression profiles, and performance traits, accelerating the development of next-generation materials.

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...

CRISPR Therapeutics (NasdaqGM:CRSP) has set new 2026 milestones, including planned regulatory submissions for Casgevy in patients aged 5 to 11. The company outlined progress in several clinical ...

When Integrated DNA Technologies (IDT) was founded in 1987 by Dr. Joseph Walder, he set his sights on a bold company vision. He believed that synthetic nucleic acids—known as oligonucleotides (oligos) ...

Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...